Related Experiment Video
Updated: Apr 30, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles
Yang Deng1, Jennifer K Saucier-Sawyer1, Christopher J Hoimes2
1Department of Biomedical Engineering, Yale University, 55 Prospect Street, MEC 414, New Haven, CT 06511, USA.
Abstract:
A key attribute for nanoparticles (NPs) that are used in medicine is the ability to avoid rapid uptake by phagocytic cells in the liver and other tissues. Poly(ethylene glycol) (PEG) coatings has been the gold standard in this regard for several decades. Here, we examined hyperbranched polyglycerols (HPG) as an alternate coating on NPs. In earlier work, HPG was modified with amines and subsequently conjugated to poly(lactic acid) (PLA), but that approach compromised the ability of HPG to resist non-specific adsorption of biomolecules. Instead, we synthesized a copolymer of PLA-HPG by a one-step esterification. NPs were produced from a single emulsion using PLA-HPG: fluorescent dye or the anti-tumor agent camptothecin (CPT) were encapsulated at high efficiency in the NPs. PLA-HPG NPs were quantitatively compared to PLA-PEG NPs, produced using approaches that have been extensively optimized for drug delivery in humans. Despite being similar in size, drug release profile and in vitro cytotoxicity, the PLA-HPG NPs showed significantly longer blood circulation and significantly less liver accumulation than PLA-PEG. CPT-loaded PLA-HPG NPs showed higher stability in suspension and better therapeutic effectiveness against tumors in vivo than CPT-loaded PLA-PEG NPs. Our results suggest that HPG is superior to PEG as a surface coating for NPs in drug delivery.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Oral Drug Delivery Systems: Delayed-Release Systems
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-Release Drug Delivery Systems: Rate-Programmed I

